BusinessProQR and Galapagos Announce Research Collaboration on Fibrosis Targets Using ProQR’s Axiomer® technologyBy Nasdaq OMXJan 8, 2018, 12:01 PM UTC
BusinessGalectin Therapeutics CEO Peter G. Traber, M.D. Named Chair of the Anti-Fibrotic Drug Development Summit 2017By Nasdaq OMXNov 13, 2017, 2:01 PM UTC
BusinessGalectin Therapeutics to Present Clinical Data at The Liver Meeting® 2017 Demonstrating the Ability of Non-Invasive Test to Identify Clinically Significant Portal Hypertension in Patients with Compensated NASH CirrhosisBy Nasdaq OMXOct 20, 2017, 12:30 PM UTC
BusinessGalectin Therapeutics launches the Liver Line, an online community and publication on liver health and liver diseaseBy Nasdaq OMXMay 3, 2017, 12:31 PM UTC
BusinessGalectin Therapeutics launches the Liver Line, an online community and publication on liver health and liver diseaseBy Nasdaq OMXMay 3, 2017, 12:31 PM UTC
BusinessGalectin Therapeutics to Present at BIO CEO & Investor ConferenceBy Nasdaq OMXFeb 8, 2017, 1:30 PM UTC
BusinessFibroGen Announces Publication of Pamrevlumab (FG-3019) Clinical Data in Pancreatic Cancer Showing Safety and Improved Survival Outcomes in Combination with ChemotherapyBy Nasdaq OMXFeb 3, 2017, 4:06 PM UTC
BusinessGalectin Therapeutics Announces Positive New Psoriasis and Atopic Dermatitis Clinical Data, Seeking Strategic Partnerships for Therapy of Severe Skin DiseasesBy Nasdaq OMXNov 10, 2016, 1:00 PM UTC
